跳至主要内容
临床试验/NCT03220399
NCT03220399撤回1 期

Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2 in Healthy Male Volunteers

NVP Healthcare0 个研究点开始时间: 2019年12月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
撤回
发起方
主要终点
Pharmacokinetic interaction

研究概览

简要总结

The purpose of this study is to compare the pharmacokinetics and safety/tolerability between NVP-1603-1 and NVP-1603-2

详细描述

pharmacokinetics and safety/tolerability between NVP-1603-1 and NVP-1603-2

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Men 19years of age or older at screening test.
  • BMI of >18.5kg/㎡ and <27.0kg/㎡ subject, weight more than 50kg.
  • Subject has signed and dated informed consent.

排除标准

  • Treatment with an investigational product (Phase I study or Biological study) within 3month preceeding the first dose of study medication.
  • History of (or presence) study medication absortion, distribution, metabolism(e.g., liver/ductal, kidney, cardio-vascular, endocrine, respiratory, GI, hematology, oncology, CNS, musculo-skeletal) or related past medical/surgery history
  • Current alcohol abuse.

研究组 & 干预措施

NVP-1603-1 (P)

Experimental

Drug: NVP-1603-1

1capsule, oral dosing

干预措施: NVP-1603-1 (P) (Drug)

NVP-1603-2(T)

Experimental

Drug: NVP-1603-2

1Tablet, oral dosing

干预措施: NVP-1603-2 (T) (Drug)

NVP-1603-1and NVP-1603-2 (P+T)

Experimental

Drug: NVP-1603-1, 1capsule and NVP-1603-2, 1Tablet co-adminstration (oral dosing)

干预措施: NVP-1603-1 and NVP-1603-2 (P+T) (Drug)

结局指标

主要结局

Pharmacokinetic interaction

时间窗: 0h - 48hrs

Area under the curve (AUC)

次要结局

未报告次要终点

研究者

发起方
NVP Healthcare
申办方类型
Industry
责任方
Sponsor

相似试验